Home
NewsNewsOTO Launches Fertility Diagnostic Wearable featuring Cira, new patented biometric and AI-powered wrist-worn biosensor technology designed to decode reproductive preparedness with precision and personalized insights.
OTO Fertility, which is a digital health platform that has been developed by OTO Coach, is going ahead and redefining the gamut of reproductive care through patented biometric and AI-powered tech that is designed to bring in much clarity and accuracy, along with confidence, when it comes to fertility treatment. At the Consumer Electronic Show - CES 2026 that was held in Las Vegas, OTO Launches Fertility Diagnostic Wearable called Cira™, which is its newest wrist-worn fertility biosensor, hence marking a prominent advancement in how the patients as well as clinics understand and also support reproductive preparedness.
Built in order to support every path to parenthood, right from natural conception to the spectrum of IVF as well as IUI, the OTO Fertility solution mixes real-time physiological data along with exact guidance that aids the patients as well as fertility care teams to make better-informed decisions at times that matter most.
The technology by OTO is rooted in over 40 years of bioscience as well as space medicine, originally created by NASA for astronauts and thereafter refined for elite human performance. Due to the launch of Cira, the patented biometric and AI-powered tech, this level of physiological accuracy is now rolled out by way of a comfortable wristband paired along with the FDA-approved app by OTO. Together, they track over fifty biometric markers, and that too only in minutes, which includes heart rate variability, nervous system regulation along with stress response, thereby translating intricate biology into a much clearer and actionable OTO Fertility Index.
This kind of index identifies when the body happens to be in an optimized fertility zone and offers insight that goes far beyond the traditional fertility elements of measure like age, BMI, or even AMH. For the very first time, women can go on to clearly witness when their body is actually ready to conceive, thereby restoring that much-needed autonomy and confidence along with control in a process that in the past has been defined by uncertainty.
Until now, fertility care has been present without any kind of visibility when it comes to the most fundamental factor, and that is how the body is responding to and also recovering from the stress in real time, remarked the Founder and CEO of OTO, Caleb Evans. Due to Cira as well as the OTO Fertility platform app, patients gain that much-needed clarity and agency, while the clinicians, on the other hand, gain a crucial new layer of that physiological context to guide care. They do not replace the currently existing fertility protocols, but they make them much smarter and safer as well as proactive.
It is well to be noted that internationally, one in every six women goes on to experience infertility, and in spite of decades of innovation, fertility treatment success rates have actually plateaued. The fact is that when we talk of fertility care, time happens to be that one resource that cannot be replaced. Every cycle along with intervention, and also every decision, goes on to carry emotional, physical as well as financial weight. OTO Fertility can be regarded as the first platform that is built to help decrease that avoidable loss along with poorly timed interventions, and at the same time the risk of proceeding sans comprehending if the body is actually prepared, thereby bringing a new benchmark of care within the reproductive medicine space.
It is worth noting that OTO Launches Fertility Diagnostic Wearable Cira wristband and the OTO Fertility platform, along with the OTO Life app, which are going to be showcased at CES 2026 to be held in Las Vegas at the Venetian, with availability expanding well throughout North America via partner fertility clinics and clinical programs that are presently underway.
A new Ipsos survey commissioned by Fertility Matters Canada finds 49% of Canadians with an opinion support a national baseline for IVF funding support, with backing rising to 59% among those aged 18–34. One in eight Canadians say cost has already forced them or someone close to delay or abandon fertility treatment.
Alpha Controls & Instrumentation Inc. has been selected by FertiTech Canada Inc. as its third-party calibration partner for Nilotech temperature probes. The partnership channels Canadian IVF laboratories and fertility clinics using Nilotech equipment to Alpha Controls for professional, accredited calibration services, while FertiTech continues to handle equipment supply and gas sensor calibration.
In the UK, a Ten Minute Rule Bill has been introduced in the Commons to create a legal right to paid time off for fertility treatment, aiming to standardize access to time‑sensitive appointments and reduce reliance on employer discretion. The proposal seeks House permission to proceed and spotlights workplace rights during Fertility Awareness Week.
Columbia University Fertility Center has achieved the first confirmed pregnancy using an AI-guided sperm recovery method in a man with azoospermia, as detailed in The Lancet. The STAR system combined advanced imaging, microfluidics, and robotics to retrieve two viable sperm, enabling embryo creation after prior failed surgical and manual attempts.
British Columbia's free IVF program exhausts 2025 funding within months of launch. At least one approved clinic stops accepting new applications. Applicants face aging-out risks and must wait until spring 2026 for next funding allocation.
Singapore’s MOH approves 13 additional genetic conditions for testing before embryos are implanted during IVF, enhancing reproductive genetic screening options.
National Health Service-funded IVF in England varies across regions in terms of access, cycle definitions, and eligibility. While Integrated Care Boards follow NICE guidelines, local implementation differs to meet specific population needs. Current policy reviews aim to enhance consistency and ensure continued access to fertility services across England.
